March 2026 Research Update

This month included human treatment evidence suggesting that some people with difficult-to-control autoimmune blood destruction may still respond to targeted immune treatments, but the strength of evidence varies widely. A multicenter real-world study reported that fostamatinib helped a meaningful portion of patients with refractory warm autoimmune hemolytic anemia and Evans syndrome, often alongside steroid reduction, while also reporting side effects that sometimes required changing therapy. Two individual case reports described long remissions after complex or tailored immune treatments, but single-patient experiences cannot show how often this happens or who is most likely to benefit. [1] [2] [3]

In routine-care data across centers, fostamatinib (a spleen tyrosine kinase inhibitor) was linked with a 46% durable response and steroid reduction in 73% of treated patients, with hypertension, stomach or bowel symptoms, or low neutrophils reported in 23%. The study also noted that a small subgroup analysis (8 patients) found certain immune markers that tracked with response, which hints at future ways to match treatments to patients, but it is too early to use this for decision-making. This adds a clearer picture that targeted immune pathways are being actively tested in refractory disease, with both potential benefit and tolerability issues to weigh in future research. [1]

Two case reports added examples of individualized approaches when Evans syndrome does not respond to standard therapies. One report described complete blood count recovery after combined telitacicept (a BAFF/APRIL blocker) plus mesenchymal stem cells, with remission lasting about 1 year and no infections reported in that patient. Another report described Evans syndrome as the first clue to systemic lupus erythematosus, where escalation to rituximab after partial response to initial therapies was followed by remission at 6 months. [2] [3]

For patients and caregivers, this month mainly adds perspective on what researchers are trying when Evans syndrome is difficult to control, rather than establishing a new standard approach. The fostamatinib study provides moderate real-world evidence that some refractory patients may have sustained improvement and may be able to reduce steroids, while also showing that side effects can occur and sometimes lead to dose changes. The telitacicept plus stem cell report and the lupus-associated Evans syndrome report show what is possible in individual patients, but they do not tell how likely similar results are in others. The big uncertainty that remains is how to predict who will respond to which immune-targeting therapy, although early biomarker signals in a small subgroup hint at how future studies may try to answer that. [1] [2] [3]

Two pediatric cohorts made it clearer that Evans syndrome in children often involves more than one blood cell line over time and frequently comes with broader immune problems, with many children needing treatment escalation. Across these studies, younger age at diagnosis and signs of more severe disease early on were linked with higher risk outcomes, and inherited immune problems were common when testing was done. At the same time, many children were in remission at last follow-up, showing that long-term outcomes can vary widely across families and settings. [4] [5]

In the 15-year Tunisian cohort of 50 children, severe presentation at diagnosis was tied to age under 24 months and lower hemoglobin, and steroid dependence and second-line therapy were common. The study also reported that deaths were more frequent in infants and were associated with a family history of inborn errors of immunity, while genetic testing found mutations suggestive of immune disorders in most of the children who were tested. It also reported that an ALPS diagnosis and treatment with mycophenolate mofetil or rapamycin were each associated with better survival, although these observational findings do not show that the treatments caused the difference. This points to the importance of recognizing distinct immune subtypes within Evans syndrome. [4]

The smaller Greek single-center follow-up of 6 children, tracked for as long as 13 years, emphasized how the condition can unfold in different ways over time, including shifting patterns of anemia, low platelets, and sometimes low neutrophils. Most children developed immune problems outside the blood, and infections were common but were mostly viral or mild bacterial infections in this group. Genetic testing was often not definitive, including one TNFAIP3 change of uncertain meaning, underscoring that even with modern testing, a clear single genetic explanation is not always found. [5]

For families, these studies mainly help set expectations about how variable pediatric Evans syndrome can be and why long-term follow-up often includes looking beyond blood counts alone. They suggest that very young children and those with signs pointing to an underlying immune-system disorder may face a higher-risk course in some settings, while many children still reached remission at follow-up. The findings also support the idea that genetic and immune evaluation can sometimes clarify what type of Evans syndrome a child has, although results may be inconclusive. What remains uncertain is how well these risk patterns apply to every clinic, since both studies were retrospective and included patients from specialized centers. [4] [5]

A single case report highlighted that serious infections can occur in the context of Evans syndrome treatment, especially when strong immune-suppressing medicines are being used for long periods. The report described an uncommon but important scenario: bacterial infection of a heart valve caused by Listeria in a person with Evans syndrome. While this is only one patient, it adds a concrete example of how infection risk can be part of the broader picture when immune suppression is needed. [6]

In this case, Listeria was found on blood cultures and heart imaging showed aortic valve infection, and the patient improved after 6 weeks of intravenous ampicillin with follow-up cultures becoming negative. The report also described that immune-suppressing medicines were tapered and stopped, and Evans syndrome stayed in remission during 10 months of follow-up. Because this is a single case, it cannot estimate how often this happens, but it documents a real-world risk context and a successful treatment course for that individual. [6]

For patients and caregivers, this report mainly adds awareness that severe infections are possible during periods of immune suppression, even if they are not common for every person. It does not change how most people are managed, but it reinforces why infection symptoms are taken seriously in people receiving immune-suppressing therapy. What remains uncertain is how generalizable this case is, since it reflects one person with a complex history and cannot predict risk for others. [6]